Date of Approval: January 25, 2022

FREEDOM OF INFORMATION SUMMARY

ORIGINAL ABBREVIATED NEW ANIMAL DRUG APPLICATION

ANADA 200-707

Tilmovet® AC

(tilmicosin phosphate)

Aqueous Concentrate

Swine

For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

Sponsored by:

Huvepharma EOOD

Table of Contents

I. GENERAL INFORMATION

A. File Number

ANADA 200-707

B. Sponsor

Huvepharma EOOD
5th Floor
3A Nikolay Haytov Str.
1113 Sofia, Bulgaria

Drug Labeler Code: 016592

U.S. Agent Name and Address:
Kelly Beers
Huvepharma, Inc.
525 West Park Drive
Peachtree City, GA 30269

C. Proprietary Name

Tilmovet® AC

D. Drug Product Established Name

tilmicosin phosphate

E. Pharmacological Category

Antimicrobial

F. Dosage Form

Aqueous concentrate

G. Amount of Active Ingredient

250 mg/mL

H. How Supplied

960 mL white-colored plastic bottle

I. Dispensing Status

Prescription (Rx)

J. Dosage Regimen

Administer in drinking water at a concentration of 200 mg tilmicosin per liter for 5 consecutive days.

K. Route of Administration

Oral, in drinking water

L. Species/Class

Swine

M. Indications

For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

N. Reference Listed New Animal Drug (RLNAD)

Pulmotil™ AC; tilmicosin phosphate; NADA 141-361; Elanco US Inc.

II. BIOEQUIVALENCE

The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Generic Animal Drug and Patent Term Restoration Act (GADPTRA) of 1988, allows for an abbreviated new animal drug application (ANADA) to be submitted for a generic version of an approved new animal drug (RLNAD). The ANADA sponsor is required to show that the generic product is bioequivalent to the RLNAD, which has been shown to be safe and effective. Effectiveness, target animal safety and human food safety data (other than tissue residue data) are not required for approval of an ANADA. If bioequivalence is demonstrated through a clinical endpoint study in a food-producing animal, then a tissue residue study to establish the withdrawal period for the generic product is also required. For certain dosage forms, the agency will grant a waiver from the requirement to perform *in vivo* bioequivalence studies (biowaiver) (55 FR 24645, June 18, 1990; Fifth GADPTRA Policy Letter; Bioequivalence Guideline, October 9, 2002).

Based on the formulation characteristics of the generic product, Huvepharma EOOD, was granted a biowaiver for the generic product Tilmovet® AC (tilmicosin phosphate) aqueous concentrate. The generic drug product is a aqueous concentrate, contains the same active ingredient in the same concentration and dosage form as the RLNAD, and contains no inactive ingredients that may significantly affect the bioavailability of the active ingredient. The RLNAD is Pulmotil™ AC (tilmicosin phosphate) aqueous concentrate, sponsored by Elanco US Inc., under NADA 141-361, and was approved for use in swine on February 13, 2014.

III. HUMAN FOOD SAFETY

The tolerances for residues and withdrawal period established for the RLNAD apply to the generic product. The following are assigned to this product for swine:

A. Acceptable Daily Intake and Tolerances for Residues

The acceptable daily intake (ADI) for total residues of tilmicosin is 25 µg/kg of body weight per day. The tolerances established for the RLNAD apply to the generic product. A tolerance of 7.5 ppm is established for tilmicosin (the marker residue) in swine liver (the target tissue), and 0.1 ppm in swine muscle, under 21 CFR 556.735.

B. Withdrawal Period

Because a biowaiver was granted, the withdrawal periods are those previously assigned to the RLNAD product. A withdrawal period of 7 days has been established for tilmicosin phosphate in swine.

C. Analytical Method for Residues

The validated analytical method for analysis of residues of tilmicosin phosphate is on file at the Center for Veterinary Medicine, 7500 Standish Place, Rockville, MD 20855. To obtain a copy of the analytical method, please submit a Freedom of Information request to: https://www.accessdata.fda.gov/scripts/foi/FOIRequest/requestinfo.cfm.

IV. USER SAFETY

The product labeling contains the following information regarding safety to humans handling, administering, or exposed to Tilmovet® AC:

WARNING
Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin.

Avoid ingestion. Avoid direct skin and eye contact. In case of human exposure, call 1-877-994-4883 and consult a physician immediately.

NOTE TO THE PHYSICIAN:
The cardiovascular system is the target of toxicity and should be monitored closely. The primary cardiac effects are tachycardia and decreased contractility. Cardiovascular toxicity may be due to calcium channel blockade.

See User Safety Warnings for additional information.

WARNINGS:
USER SAFETY WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. SEE BOXED WARNING AND NOTE TO THE PHYSICIAN FOR ADDITIONAL INFORMATION. Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water. To report suspected adverse drug events,

for technical assistance or to obtain a copy of the Safety Data Sheet, contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.

V. AGENCY CONCLUSIONS

The data submitted in support of this ANADA satisfy the requirements of section 512(c)(2) of the FD&C Act. The data demonstrate that Tilmovet® AC, when used according to the label, is safe and effective for the indications listed in Section I.M. above.

Additionally, data demonstrate that residues in food products derived from swine treated with Tilmovet® AC will not represent a public health concern when the product is used according to the label.